Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides reagents, instruments, software, and consumables; arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment focused on production of synthesized oligonucleotides for use as active pharmaceutical ingredients. The Agilent CrossLab segment offers GC and LC columns, sample preparation products, custom chemistries, and various laboratory instrument supplies; and startup, operational, training, compliance support, and software as a service, as well as asset management and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was founded in 1999 and is headquartered in Santa Clara, California.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
Phone408-345-8886
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.91 billion
Profitability
Miscellaneous
Employees14,800
Next Earnings Date8/13/2019 (Estimated)
OptionableOptionable
Agilent Technologies (NYSE:A) Frequently Asked Questions
What is Agilent Technologies' stock symbol?
Agilent Technologies trades on the New York Stock Exchange (NYSE) under the ticker symbol "A."
How often does Agilent Technologies pay dividends? What is the dividend yield for Agilent Technologies?
Agilent Technologies declared a quarterly dividend on Thursday, March 21st. Investors of record on Tuesday, April 2nd will be paid a dividend of $0.164 per share on Wednesday, April 24th. This represents a $0.66 annualized dividend and a yield of 0.95%. The ex-dividend date is Monday, April 1st. View Agilent Technologies' Dividend History.
How will Agilent Technologies' stock buyback program work?
Agilent Technologies declared that its board has approved a stock buyback plan on Monday, November 19th 2018, which authorizes the company to buyback $1,750,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 8.8% of its shares through open market purchases. Shares buyback plans are usually an indication that the company's board of directors believes its shares are undervalued.
How were Agilent Technologies' earnings last quarter?
Agilent Technologies Inc (NYSE:A) issued its quarterly earnings data on Tuesday, May, 14th. The medical research company reported $0.71 EPS for the quarter, missing analysts' consensus estimates of $0.72 by $0.01. The medical research company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.27 billion. Agilent Technologies had a net margin of 22.25% and a return on equity of 19.71%. The company's revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.65 EPS. View Agilent Technologies' Earnings History.
When is Agilent Technologies' next earnings date?
What guidance has Agilent Technologies issued on next quarter's earnings?
Agilent Technologies updated its FY19 earnings guidance on Tuesday, May, 14th. The company provided earnings per share (EPS) guidance of $3.03-3.07 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.07. The company issued revenue guidance of $5.09-5.13 billion, compared to the consensus revenue estimate of $5.19 billion.Agilent Technologies also updated its FY 2019 guidance to $3.03-3.07 EPS.
What price target have analysts set for A?
13 Wall Street analysts have issued 12-month target prices for Agilent Technologies' stock. Their predictions range from $82.00 to $92.00. On average, they anticipate Agilent Technologies' stock price to reach $86.4545 in the next year. This suggests a possible upside of 25.1% from the stock's current price. View Analyst Price Targets for Agilent Technologies.
What is the consensus analysts' recommendation for Agilent Technologies?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agilent Technologies in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agilent Technologies.
What are Wall Street analysts saying about Agilent Technologies stock?
Here are some recent quotes from research analysts about Agilent Technologies stock:
- 1. According to Zacks Investment Research, "Agilent reported weak fiscal second-quarter results due to slowing global demand in small molecule Pharma and softness in the China Food market. However, Agilent saw notable improvement across its other product lines. Moreover, its strengthening position in Americas, China and Europe remain the key growth drivers. Additionally, the company’s decision to wind up its underperforming businesses is benefiting its core operations. Further, the company’s focus on aligning investments towards more attractive growth avenues and innovative high-margin product launches are major positives. Notably, the stock has underperformed the industry it belongs to over a year. However, macro weakness in some regions and unfavorable foreign exchange remain concerns. Also, higher expenses are making margin expansion difficult for the company." (5/16/2019)
- 2. Barclays PLC analysts commented, "We think Agilent delivered a solid FY1Q19 print last night, featuring a modest top line beat which was leveraged into a 6% EPS beat ($0.76 vs. our $0.72 forecast). Consistent trends help improve our conviction in the thesis heading into FY2019. Organic growth of 6% in the quarter came in 1.2% better than our expectations and guidance. Growth was solid, although less broad-based than last quarter – which we view as understandable in the context of tough quarterly comps. Notably, DGG posted 13% organic growth while ACG delivered 10% organic growth. The capital equipment driven LSAG division posted just" 1% organic growth, but on an 11% quarterly comp. From an end market perspective, we think results hit the mark across customer classes and geographies. Pharma & Sales) posted 10% core growth." (2/21/2019)
Has Agilent Technologies been receiving favorable news coverage?
News headlines about A stock have trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Agilent Technologies earned a coverage optimism score of 1.9 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are some of Agilent Technologies' key competitors?
Some companies that are related to Agilent Technologies include Illumina (ILMN), Mettler-Toledo International (MTD), Waters (WAT), PerkinElmer (PKI), Bio-Rad Laboratories (BIO.B), Bio-Rad Laboratories (BIO), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Fluidigm (FLDM), Quanterix (QTRX), Eyepoint Pharmaceuticals (EYPT) and Harvard Bioscience (HBIO).
What other stocks do shareholders of Agilent Technologies own?
Who are Agilent Technologies' key executives?
Agilent Technologies' management team includes the folowing people:
- Mr. Michael R. McMullen, CEO, Pres & Director (Age 58)
- Mr. Robert W. McMahon, Sr. VP & CFO (Age 50)
- Mr. Dominique P. Grau, Sr. VP of HR (Age 60)
- Mr. Mark Doak, Sr. VP (Age 64)
- Mr. Jacob Thaysen, Sr. VP (Age 44)
Who are Agilent Technologies' major shareholders?
Agilent Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.86%), Wellington Management Group LLP (2.66%), OppenheimerFunds Inc. (2.63%), Artisan Partners Limited Partnership (1.84%), FMR LLC (1.77%) and American Century Companies Inc. (1.55%). Company insiders that own Agilent Technologies stock include Boon Hwee Koh, Didier Hirsch, Dominique Grau, Heidi Fields, Jacob Thaysen, James Cullen, Mark Doak, Michael R Mcmullen, Michael Tang, Patrick G Hagan, Patrick Kaltenbach, Paul N Clark and Rodney Gonsalves. View Institutional Ownership Trends for Agilent Technologies.
Which institutional investors are selling Agilent Technologies stock?
A stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Wells Fargo & Company MN, Findlay Park Partners LLP, Morgan Stanley, AQR Capital Management LLC, Factory Mutual Insurance Co., Candriam Luxembourg S.C.A. and Natixis. Company insiders that have sold Agilent Technologies company stock in the last year include Boon Hwee Koh, Dominique Grau, Heidi Fields, Mark Doak, Michael R Mcmullen, Michael Tang, Paul N Clark and Rodney Gonsalves. View Insider Buying and Selling for Agilent Technologies.
Which institutional investors are buying Agilent Technologies stock?
A stock was bought by a variety of institutional investors in the last quarter, including SEI Investments Co, American Century Companies Inc., Man Group plc, Geode Capital Management LLC, Royal London Asset Management Ltd., MERIAN GLOBAL INVESTORS UK Ltd, Renaissance Technologies LLC and Cookson Peirce & Co. Inc.. View Insider Buying and Selling for Agilent Technologies.
How do I buy shares of Agilent Technologies?
Shares of A can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agilent Technologies' stock price today?
One share of A stock can currently be purchased for approximately $69.11.
How big of a company is Agilent Technologies?
Agilent Technologies has a market capitalization of $21.94 billion and generates $4.91 billion in revenue each year. The medical research company earns $316 million in net income (profit) each year or $2.79 on an earnings per share basis. Agilent Technologies employs 14,800 workers across the globe.
What is Agilent Technologies' official website?
How can I contact Agilent Technologies?
Agilent Technologies' mailing address is 5301 STEVENS CREEK BLVD, SANTA CLARA CA, 95051. The medical research company can be reached via phone at 408-345-8886 or via email at [email protected]
MarketBeat Community Rating for Agilent Technologies (NYSE A)
MarketBeat's community ratings are surveys of what our community members think about Agilent Technologies and other stocks. Vote "Outperform" if you believe A will outperform the S&P 500 over the long term. Vote "Underperform" if you believe A will underperform the S&P 500 over the long term. You may vote once every thirty days.
